ADIPONECTIN VERSUS THIAZOLIDINEDIONES AND ANGIOTENSIN RECEPTOR BLOCKERS
AbstractAdipose tissue has gained great attention during the last decade. It represents not only a depot for energy stores, but also releases adipocytokines regulating energy disposal and can therefore be considered from therapeutic point of view. Hypoadiponectemia is an independent threat for development of metabolic syndrome. When subjects treated with antidiabetic (Thiazolidinediones) and antihypertensive (angiotensin receptor blocker) agents , the plasma concentration of adiponectin, the only component of adipocytokines, directly proportional to plasma values of these drugs. The prevalance of hypertension and T2DM is mounting with unprecedented degree in both developing and advanced countries, therefore, there is a dire need to find safer and economical therapeutic regimes for the treatment of these ailments, and intensive research is also underway for this purpose. PPARγ serves as a common link in the actions of ADN, TZDs and ARBs when exerting their effects, and it is responsible for stimulation of adiponectin receptors, thus ultimately enhancing the levels of adiponectin in plasma. This review aims to elucidate the role, link and use of ARBs, ADN and TZDs as a safer and convenient approach for the treatment of these co-morbidities as a unanimous or single remedy from comparative point of view.
Download data is not yet available.
How to Cite
Afzal, S., Sattar, M. A., Rathore, H. A., Hussain, A. I., Ahmad, A., Javeed, A., Ahmad, F.- ud- din, J. Johns, E., & Akhtar, S. (2013). ADIPONECTIN VERSUS THIAZOLIDINEDIONES AND ANGIOTENSIN RECEPTOR BLOCKERS. European Scientific Journal, ESJ, 9(24). https://doi.org/10.19044/esj.2013.v9n24p%p